Treatment of Gastric Cancer With Peritoneal Carcinomatosis by Cytoreductive Surgery and HIPEC: A Systematic Review of Survival, Mortality, and Morbidity

J Surg Oncol. 2011 Nov 1;104(6):692-8. doi: 10.1002/jso.22017. Epub 2011 Jun 28.

Abstract

Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis, which may be improved with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). We systematically reviewed the literature regarding the efficacy of CRS + HIPEC in these patients. Electronic databases were searched from 2000 to 2010. Following CRS + HIPEC, overall median survival was 7.9 months and improved to 15 months for patients with completeness of cytoreduction scores of 0/1, however with a 30-day mortality rate of 4.8%.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma / mortality*
  • Carcinoma / secondary
  • Carcinoma / therapy
  • Chemotherapy, Cancer, Regional Perfusion
  • Combined Modality Therapy
  • Humans
  • Hyperthermia, Induced*
  • Peritoneal Neoplasms / mortality*
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / therapy
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy
  • Survival Rate

Substances

  • Antineoplastic Agents